The text starts here.

News Release

November 1, 2001


Tokyo (November 1, 2001) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced that preparations are in process for the establishment of a 100% owned subsidiary, Eisai Farmaceutica S.A., for the marketing of prescription pharmaceuticals.

Eisai Farmaceutica will co-promote ARICEPT, an Alzheimer's disease treatment with Pfizer S.A., and PARIET, a treatment for gastrointestinal disorders, with Janssen-Cilag S.A.

The prescription pharmaceutical market in Spain is ranked 5th in the E.U. Along with Eisai's other E.U. subsidiaries in the U.K., Germany, and France, Eisai's marketing operations will cover approximately 70% of the E.U. market.

< Company Outline >

Name: Eisai Farmaceutica S.A.

Location: Madrid, Spain

President: Hideshi Honda

Shareholders' Equity Capital: Euro4,000,000 (about Yen440,000,000: 1Euro=Yen110)

Employees: Approximately 30

< Reference >

[Principal Subsidiaries in the E.U.]

Company Establishment Function(s)

Eisai GmbH (Germany) December 1989 Pharmaceutical Sales

Eisai Ltd. (U.K.) October 1995 Clinical Research/Pharma. Sales

Eisai S.A. (France) January 1996 Pharmaceutical Sales

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.